arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Cytosorbents Corp

CTSO
$0.37 ▼ -0.02 (-4.77%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
29 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cytosorbents Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $23.0M
Dividend Yield
Revenue Growth 4.1%
Op. Margin -39.8%
ROIC -62.3%
FCF / Share $-0.20
Trailing P/E
Price / Book 3.9x
FCF Yield
Debt / Equity 2.82
info Valuation on last close. End-of-day price, Aug 7, 2026.

29-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.06M
↑ +4.1%
Net Income Profit after all expenses
$-8.20M
↑ +60.4%
Operating Margin Operating profit as % of sales
-39.8%
↑ +13.9% 6th
FCF / Share Free cash flow per share
$-0.20
↑ +25.4%
Long-Term Debt Long-term obligations
$16.67M
↑ +19.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
6
Financial Health
21
Cash Quality
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 29 years · 79 quarters